Posts by Steven Chervenick
Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
Primary Outcome Measures safety of PB103 [ Time Frame: one year ] assessment of adverse events Secondary Outcome Measures efficacy of PB103 [ Time Frame: one year ] assessment of Progression Free Survival, PFS Inclusion Criteria Recipient: Recipients (Subjects) are between 20-70 years of age. Related donor: 6/6 matched at HLA-A, -B and -DRb1 or haploidentical donor ≥ 4/8 match at HLA-A, -B,…
Read MoreResearch is Showing That Mesothelioma Patients Could Benefit from Vitamin D3
Vitamin D3 could potentially be used to slow down mesothelioma. There are promising results coming from a study in Italy studying the possibilities of Vitamin D3 on mesothelioma cells. Results from the study are showing that it could prevent mesothelioma cells from growing and spreading. Calcitriol, the biologically active form of Vitamin D3, has shown…
Read MoreReducing UHRF1 Could Lengthen Mesothelioma Sufferers’ Lives
The protein UHRF1 could help people survive pleural mesothelioma. Research from the National Cancer Institute found this protein. The protein is encoded by the gene with the same name. Researchers in the study believe that it could cause the growth and spread of mesothelioma. The information needs to be confirmed with a larger study but…
Read MoreA New T-Cell Treatment is Being Tested on Mesothelioma Patients
A new clinical trial at the Memorial Sloan Kettering Cancer Center is recruiting patients for a pleural mesothelioma study. The treatment involves T-cell therapy and is a very promising treatment for mesothelioma sufferers. The reason the study is being done is ATA2271, which is known as CAR T-cell therapy, was recently approved by the Food…
Read MoreMesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma
This study will test the safety of MSLN-targeted CAR-T cells at different doses to find the safest dose to give to people with MPM. The researchers want to see what effects, if any, the study treatment has on people with this type of cancer. This study is the first time that an MSLN-targeted CAR-T cell treatment with an anti-PD1 component is being given to people.
Read MoreOpdivo and Yervoy Have Been Fully Approved for Treating Mesothelioma
A new treatment has been approved for mesothelioma by the Food and Drug Administration (FDA). The treatment uses a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), which are immunotherapy drugs created by Bristol-Myers Squibb. It is the first new drug combination approved for mesothelioma in 16 years. The most recent approved treatment involved Tumor Treating…
Read MoreNew Immuno-Radiology Treatment Being Tested on Mesothelioma
Mesothelioma is a cancer with a bad prognosis that is primarily caused by asbestos exposure. There is no cure for mesothelioma, so people diagnosed with the disease do not have a great chance of living long past their diagnoses. Clinical trials are people’s best chance of finding a better treatment or even a cure, so…
Read MoreMesothelioma Trial Involving UV1 Cancer Vaccine and Immunotherapy
A new mesothelioma clinical trial is taking place in Oslo, Norway. The trial is looking at the UV1 cancer vaccine alongside immunotherapy. The vaccine is a peptide-based drug that activates a T-cell response, allowing the immunotherapy drugs to work better. This will be the first time that UV1 is being tested on mesothelioma, but it…
Read MoreA Two-part Study to Characterize Drug-Drug Interaction Effects on Steady-State Pharmacokinetics of Oral Tazemetostat
This is a phase I, multi-center, open-label, multi-dose, two-part PK and safety study to characterize the DDI potential of oral Tazemetostat.
Read MoreQuinacrine has Anti-Cancer Effects on Mesothelioma Cells
Pleural mesothelioma is a devastating cancer of the mesothelium, which is a lining of different organs. The most common type of mesothelioma is pleural, which affects the lining of the lungs while the second most common is peritoneal, which surrounds the lining of the abdomen. New treatments are constantly being developed for the cancer, but…
Read More